OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Operating Cash Flow
Cash generated by the company's core business operations during the period.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $12.94M (cash outflow) fell 7.6% year over year, behind the -2.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -7.6% toward the trailing-twelve-month pace of -2.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (51.83M) USD
- Year-over-year change
- -1.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (51.83M) | -1.4% |
| FY2024 | 2024-12-31 | (51.12M) | -48.0% |
| FY2023 | 2023-12-31 | (34.55M) | -28.2% |
| FY2022 | 2022-12-31 | (26.95M) | +29.0% |
| FY2021 | 2021-12-31 | (37.98M) | — |
Operating Cash Flow vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's LTM Mar 2026 operating cash flow of $50.76M is the 3rd largest of the 4 companies compared; the peer median is $56.31M.
- Its year-over-year change of -2.7% is the 2nd highest of 4, against a peer median of -26.2%.
- Over three fiscal years its annual growth of +24.4% compares with a peer median of +433.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.39B | +12765.8% | +925.8% | — | |
| LTM Mar 2026 | $56.31M | -366.9% | -59.6% | 105.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $50.76M | -2.7% | +24.4% | — |
| LTM Jun 2026 | $22.66M | -26.2% | — | 64.6% | |
| Peer median (excluding OKUR) | $56.31M | -26.2% | +433.1% | 84.9% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 48K | 199K | 4.53M | 11.63M |
| Change in Working Capital | (2.8M) | 2.12M | 6K | (3.95M) | (4.78M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 1.71M | (5.93M) | (4.55M) |
| Other Working Capital | (2.8M) | 2.12M | (1.71M) | 1.98M | (235K) |
| Other Non-Cash Items | 4.54M | 0 | 0 | 316K | 6K |
| Operating Cash Flow | (37.98M) | (26.95M) | (34.55M) | (51.12M) | (51.83M) |
| Capital Expenditures | (198K) | (1.13M) | (246K) | (52K) | (46K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (31.41M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.23M | 44.1M | 0 | 15.93M | 0 |
| Other Investing Activities | 0 | (44.1M) | 0 | 0 | 0 |
| Investing Cash Flow | (23.38M) | (1.13M) | (246K) | 15.87M | (46K) |
| Debt Repayment | 0 | 0 | 0 | 6M | 0 |
| Common Stock Issued | 132.41M | 340K | 65K | 58.91M | 203K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.38M) | (723K) | 51.22M | (40K) |
| Financing Cash Flow | 132.41M | 26.47M | 53.13M | 116.13M | 163K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.05M | (1.62M) | 18.33M | 80.89M | (51.71M) |
| Free Cash Flow | (38.18M) | (28.09M) | (34.79M) | (51.17M) | (51.87M) |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.